For more information call (888) LUHS-888.
Patients must be 18 years or older with a pathologically proven diagnosis of intermediate-risk adenocarcinoma of the prostate. The patients must have a Gleason score of 7, PSA greater than 10 but less than or equal to 20 and be tumor stage T2b-T2c. Patients must have clinically negative lymph nodes. Patients may not have received prior hormonal therapy, prior or concurrent cytotoxic therapy for prostate cancer or prior radiotherapy to the region of the study cancer.
The purpose of this study is to compare the effects of radiation therapy with or without hormone therapy on individuals with intermediate-risk prostate cancer.